Previous studies have reported the relationship between the risk of developing pancreatic cancer and blood groups. There have been conflicting results with respect to the prognostic significance of the AB0 blood group in pancreas cancer. We aimed to evaluate the impacts of blood groups on prognosis in our pancreatic cancer patient population. Patients diagnosed with pancreas cancer between January 2014 and December 2018 were analyzed retrospectively. We analyzed the prognostic significance of AB0 blood groups for PDAC (pancreatic ductal adenocarcinoma) patients based on stages of the disease (early stage, locally advanced stage, and metastatic). We evaluated 366 patients diagnosed with pancreatic cancer. The median age of the patients was 65 (27-83). The median overall survival (OS) was 11 months (95%9.49-12.50 months). Median survival based on blood groups were as follows: 13 months for blood group A (95% Cl, 10.59-15.41), 11 months for blood group B (95% Cl, 8.80-13.19), 12 months for blood group AB (95% 6.63-17.36), and eight months for blood group 0 (95% Cl, 5.43-10.56) (p = 0.171). 304 (83.3%) of the patients were not alive at the end of the study. We concluded that the survival of those with 0 blood group was shorter in patients with metastatic pancreatic cancer (p <0.001), taking into account the relationship between stages and blood groups. There was no prognostic effect of AB0 blood groups on pancreatic cancer in our patient group. However, we found that blood group 0 negatively affected OS in metastatic pancreas cancer patients, based on the subgroup analysis according to stages.